Nebenwirkungen · Arixtra
Arixtra 2.5 mg/0.5 ml solution for injection, pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 20
HOS-110122 · Präparat HOS-093307
The safety of fondaparinux has been evaluated in: - 3,595 patients undergoing major orthopaedic surgery of the lower limbs treated up to 9 days (Arixtra 1.5 mg/0.3 ml and Arixtra 2.5 mg/0.5 ml) - 327 patients undergoing hip fracture surgery treated for 3 weeks following an initial prophylaxis of 1 week (Arixtra 1.5 mg/0.3 ml and Arixtra 2.5 mg/0.5 ml) - 1,407 patients undergoing abdominal surgery treated up to 9 days (Arixtra 1.5 mg/0.3 ml and Arixtra 2.5 mg/0.5 ml) - 425 medical patients who are at risk for thromboembolic complications treated up to 14 days (Arixtra 1.5 mg/0.3 ml and Arixtra 2.5 mg/0.5 ml) - 10,057 patients undergoing treatment of UA or NSTEMI ACS (Arixtra 2.5 mg/0.5 ml) - 6,036 patients undergoing treatment of STEMI ACS (Arixtra 2.5 mg/0.5 ml) - 2,517 patients treated for Venous Thrombo-Embolism and treated with fondaparinux for an average of 7 days (Arixtra 5 mg/0.4 ml, Arixtra 7.5 mg/0.6 ml and Arixtra 10 mg/0.8 ml).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage a4d44fd2e27fc3d75866f416b6ac9ae5e481febb1fc2645b5eebb07a498a29eb · Zeichen 333–1342 im Abschnitt